GlassScriptPhysician profile
Michael T Couris
NPI 1063638682
$11,075.51
in general payments reported to CMS, 2019-2025
32 companies · $3,179 in 2025
The $3,179 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $557 · 2021: $1,245 · 2022: $1,644 · 2023: $1,531 · 2024: $2,682 · 2025: $3,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,392.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,342.12 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Alcon Vision LLC | $1,253.87 | 2019-2025 | Clareon, Rocklatan, Clareon Panoptix Pro |
| Bausch & Lomb Americas INC. | $1,108.90 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Amgen INC. | $857.59 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $786.39 | 2020-2025 | Acthar |
| Ocular Therapeutix, INC. | $737.47 | 2023-2025 | Dextenza |
| Allergan, INC. | $681.78 | 2019-2022 | |
| Horizon Therapeutics Plc | $642.95 | 2021-2023 | Tepezza |
| Glaukos Corporation | $459.13 | 2020-2025 | Idose, Idosetr |
| Tarsus Pharmaceuticals, INC. | $382.40 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $329.63 | 2022-2025 | Oxervate |
| Harrow Eye, LLC | $295.00 | 2024-2025 | Vevye, Iheezo |
| Oyster Point Pharma, INC. | $282.85 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $237.17 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $234.69 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $196.99 | 2019-2022 | |
| Baxter Healthcare | $168.71 | 2022 | |
| Sight Sciences, INC. | $167.29 | 2020-2024 | Omni Surgical System, Tearcare System |
| Biotissue Holdings INC. | $145.06 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $137.94 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $135.64 | 2019-2022 | |
| Lilly USA, LLC | $115.95 | 2025 | Zepbound |
| New World Medical,INC. | $106.11 | 2022 | |
| Thea Pharma INC. | $66.53 | 2023-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $61.20 | 2025 | |
| Nova Eye, INC. | $31.99 | 2024 | |
| Rayner Intraocular Lenses Limited | $23.20 | 2025 | Rayone Spheric, Rayner Cataract Set 1, Rayone Aspheric |
| Boston Scientific Corporation | $21.28 | 2021 | |
| Rxsight INC | $20.75 | 2021 | |
| Lumenis, INC | $20.12 | 2021 | |
| Ivantis, INC | $18.16 | 2020 | |
| Notal Vision, INC. | $6.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Couris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.